How Will the Curosurf (Poractant Alfa) Market Grow? Key Trends and Opportunities for 2025 and Beyond
Updated 2025 Market Reports Released: Trends, Forecasts to 2034 – Early Purchase Your Competitive Edge Today!
How Will the Curosurf (Poractant Alfa) Market Grow Over the Forecast Period Based on Its Expected CAGR?
In recent years, there has been a steady growth in the market size of Curosurf (poractant alfa), recording an CAGR of XX. It is projected that the market will advance from a $XX million in 2024 to $XX million in 2025, showing a compound annual growth rate (CAGR) of XX%. This escalation in the historical phase is a result of increased inclination towards sophisticated medical solutions, heightened demand for synthetic surfactants in hygiene products, broader healthcare awareness, improved healthcare access, a growing preference for effortless cleanliness driving synthetic surfactant sales, as well as a further increase in healthcare awareness.
In the coming years, the curosurf (poractant alfa) market is predicted to exhibit a XX (CAGR) growth, expanding to $XX million in 2029 with a compound annual growth rate (CAGR) of XX%. The growth during this forecast period is likely due to the escalating rates of premature births, the expanding use of synthetic surfactants in farming chemicals, higher occurrence of chronic respiratory conditions, augmented health expenses, and a growing preference for remedial actions for respiratory infections. Major market trends expected in the forecast period include the implementation of microdosing strategies, incorporation of surfactant therapies, use of biologic and immunomodulatory therapies, a lean towards sustainable and eco-friendly surfactants, and an emphasis on neonatal and pediatric healthcare.
What Major Innovations Are Driving the Accelerated Growth of the Curosurf (Poractant Alfa) Market?
The surge in respiratory disorders is anticipated to fuel the growth of the curosurf (poractant alfa) market in the future. Respiratory disorders involve frequent medical conditions impacting the lungs and breathing process, including ailments like asthma, COPD, and lung cancer. They cause breathing problems and diminish lung functionality. The rising occurrence of respiratory disorders is contributed to increasing air contamination, which intensifies ailments like asthma and a growing elderly populace that leads to the prevalence of age-associated disorders like COPD. Poractant alfa is utilised to handle neonatal respiratory distress syndrome by promoting lung function and helping premature infants with breathing through insertion via an endotracheal tube. For example, the National Asthma Council, an Australia-based non-profit association reported that in November 2023, Australia recorded 467 asthma-related fatalities, a figure up from the 355 deaths reported in 2021. Thus, the swelling prevalence of respiratory disorders is fueling the expansion of the curosurf (poractant alfa) market.
Get Your Free Sample of the Global Curosurf (Poractant Alfa) Market Report Now!
https://www.thebusinessresearchcompany.com/sample.aspx?id=19893&type=smp
Who Are the Dominant Players Expanding Their Reach in the Curosurf (Poractant Alfa) Market?
Major companies operating in the curosurf (poractant alfa) market include Chiesi Farmaceutici S.p.A
What Are the Top Trends Shaping the Evolution of the Curosurf (Poractant Alfa) Market?
A major trend in the curosurf (poractant alfa) market is the emphasis on developing inventive solutions, such as cutting-edge inhaled gene therapy, to meet the unresolved needs in respiratory diseases. The term “novel inhaled gene therapy” refers to a groundbreaking method where therapeutic genes are directly transported to the lungs through inhalation, usually via aerosolized particles or nanoparticles. For example, in November 2024, UK-based gene therapy developer AlveoGene was granted the Rare Pediatric Disease Designation (RPDD) by the FDA for its product AVG-002, an innovative inhaled gene therapy aimed at combating lethal neonatal surfactant protein B (SP-B) deficiency, an intense genetic disorder resulting in respiratory failure in infants. With SP-B deficiency, caused by mutations in the SFTPB gene, the treatment options are quite limited and largely depend on lung transplantation. AVG-002 utilizes AlveoGene’s InGenuity platform to transport a functional SP-B gene straight to the lungs and has exhibited encouraging outcomes in preliminary studies.
Get Instant Access to the Global Curosurf (Poractant Alfa) Market Report with Swift Delivery!
https://www.thebusinessresearchcompany.com/report/curosurf-poractant-alfa-global-market-report-
Which Market Segments Are Driving Strategic Growth and Trends in the Curosurf (Poractant Alfa) Market?
The curosurf (poractant alfa)market covered in this report is segmented –
1) By Type: Natural Poractant Alfa; Synthetic Poractant Alfa
2) By Sales Channel: Direct Sales; Distribution Channels; Online Marketplace
3) By Application: Pulmonary Edema; Respiratory Distress Syndrome; Other Respiratory Disorders
4) By End User: Hospitals; Clinics; Ambulance Services
Which Regions Are Setting the Pace for Curosurf (Poractant Alfa) Market Growth?
North America was the largest region in the curosurf (poractant alfa) market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the curosurf (poractant alfa) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
How Is the Curosurf (Poractant Alfa) Market Defined Across Different Regions?
Curosurf (poractant alfa) refers to a synthetic pulmonary surfactant used primarily for the treatment and prevention of respiratory distress syndrome (RDS) in preterm neonates. It is a synthetic version of a natural substance called pulmonary surfactant, which is produced in the lungs to help reduce surface tension and prevent the collapse of the alveoli (small air sacs) in the lungs.
Browse Through More Similar Reports By The Business Research Company:
Anti-Vascular Endothelial Growth Factor Therapeutics Global Market Report 2025
Vascular Endothelial Growth Factor (VEGF) Inhibitor Global Market Report 2025
Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Global Market Report 2025
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Contact us at:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at [email protected]
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
Found this article helpful? Share it on:
